U.S. patent application number 17/027761 was filed with the patent office on 2021-01-07 for sphingosine pathway modulating compounds for the treatment of cancers.
This patent application is currently assigned to Enzo Biochem, Inc.. The applicant listed for this patent is Enzo Biochem, Inc.. Invention is credited to James J. Donegan, Elazar Rabbani.
Application Number | 20210000766 17/027761 |
Document ID | / |
Family ID | |
Filed Date | 2021-01-07 |
View All Diagrams
United States Patent
Application |
20210000766 |
Kind Code |
A1 |
Rabbani; Elazar ; et
al. |
January 7, 2021 |
SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF
CANCERS
Abstract
The invention provides methods and compositions for treating
cancers and myeloproliferative disorders using sphingosine kinase-1
inhibitors, such as SK1-I, and selective sphingosine-1-phosphate
receptor agonists, such as ozanimod.
Inventors: |
Rabbani; Elazar; (New York,
NY) ; Donegan; James J.; (Amesbury, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Enzo Biochem, Inc. |
New York |
NY |
US |
|
|
Assignee: |
Enzo Biochem, Inc.
New York
NY
|
Appl. No.: |
17/027761 |
Filed: |
September 22, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16830357 |
Mar 26, 2020 |
|
|
|
17027761 |
|
|
|
|
16287201 |
Feb 27, 2019 |
10646459 |
|
|
16830357 |
|
|
|
|
16017345 |
Jun 25, 2018 |
10278960 |
|
|
16287201 |
|
|
|
|
62524221 |
Jun 23, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
International
Class: |
A61K 31/137 20060101
A61K031/137; A61K 31/4245 20060101 A61K031/4245; A61K 45/06
20060101 A61K045/06; A61K 31/135 20060101 A61K031/135; A61P 35/00
20060101 A61P035/00; A61P 35/02 20060101 A61P035/02 |
Claims
1. A method for treating prostate cancer in a mammalian subject,
comprising the step of: administering to a mammalian subject in
need of treatment for prostate cancer an effective amount of
ozanimod or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the administering step comprises
administering the hydrochloride salt of ozanimod to the mammalian
subject.
3. The method of claim 1, wherein the mammalian subject is a
human.
4. The method of claim 3, wherein the administering step comprises
administering the hydrochloride salt of ozanimod to the mammalian
subject.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/830,357 filed Mar. 26, 2020, which is a
continuation of U.S. patent application Ser. No. 16/287,201 filed
Feb. 27, 2019 (now U.S. patent no. 10,646,459), which is a
divisional of U.S. patent application Ser. No. 16/017,345 filed
June 25, 2018 (now U.S. Pat. No. 10,278,960), which claims the
benefit of U.S. provisional patent application Ser. No. 62/524,221
filed Jun. 23, 2017, each of which is hereby incorporated by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The invention relates to the field of pharmaceutical
treatment of cancers.
BACKGROUND
[0003] Sphingosine-1-phosphate (S1P) was discovered to be a
bioactive signaling molecule over 20 years ago. Studies have since
identified two related kinases, sphingosine kinase 1 and 2 (a/k/a
sphingosine kinase "type I" and "type II" respectively, and SphK1
and SphK2 respectively), which catalyze the phosphorylation of
sphingosine to S1P. Extracellular S1P can bind to and activate each
of five S1P-specific, G protein-coupled receptors (designated
S1PR.sub.1-5) to regulate cellular and physiological processes in
an autocrine or paracrine manner. Selective inhibitors of each of
sphingosine kinase 1 and 2, as well as both non-selective and
selective agonists of S1PRs, have been developed and are known in
the art.
SUMMARY
[0004] One embodiment of the invention provides a method for
treating liver cancer, such as hepatocellular carcinoma (HCC), in a
mammalian subject, such as a human, that includes the step of:
[0005] administering to a mammalian subject in need of treatment
for liver cancer, a therapeutically effective amount of a
sphingosine kinase type I inhibitor, such as SK1-I or a
pharmaceutically acceptable salt thereof.
[0006] A related embodiment of the invention provides a
pharmaceutical composition that includes a sphingosine kinase type
I inhibitor, such as SK1-I or a pharmaceutically acceptable salt
thereof for the treatment of liver cancer, such as HCC, in a
mammal, such as a human patient.
[0007] Another embodiment of the invention provides a method for
treating a cancer or a myeloproliferative disorder
(myeloproliferative neoplasm) in a mammalian subject, such as a
human, that includes the step of:
[0008] administering to a mammalian subject in need of treatment
for a cancer or myeloproliferative disorder, a therapeutically
effective amount of a sphingosine-1-phosphate receptor agonist,
such as an agonist of one or both of sphingosine-1-phosphate
receptor-1 (S1P.sub.1) and sphingosine-1-phosphate receptor-5
(S1P.sub.5) such as ozanimod (RPC1063) or a pharmaceutically
acceptable salt thereof.
[0009] A related embodiment of the invention provides a
pharmaceutical composition for the treatment of a cancer or a
myeloproliferative disorder (myeloproliferative neoplasm) in a
mammalian subject, such as a human, that includes:
[0010] a therapeutically effective amount of a
sphingosine-1-phosphate receptor agonist, such as an agonist of one
or both of sphingosine-1-phosphate receptor-1 (S1P.sub.1) and
sphingosine-1-phosphate receptor-5 (S1P.sub.5) such as ozanimod
(RPC1063) or a pharmaceutically acceptable salt thereof.
[0011] Still another embodiment of the invention provides a method
for treating a cancer or a myleoproliferative disorder
(myeloproliferative neoplasm), such as any of those disclosed
herein, in a mammalian subject, such as a human, including the step
of:
[0012] co-administering to a mammalian subject in need of treatment
for a cancer or myeloproliferative disorder, a therapeutically
effective amount of:
[0013] (a) a sphingosine kinase type I inhibitor, such as one
disclosed in U.S. Pat. No. 8,372,888 and/or 8,314,151, such as
SK1-I, or a pharmaceutically acceptable salt thereof; and
[0014] (b) one or more immune checkpoint inhibitors, which may be
monoclonal antibodies, such as one or more selected from the group
consisting of: PD-1 inhibitors such as mAbs Pembrolizumab
(Keytruda.RTM.) and Nivolumab (Opdivo.RTM.); PD-L1 inhibitors such
as mAbs Atezolizumab (Tecentriq.RTM.), Avelumab (Bavencio.RTM.),
and Durvalumab (Imfinzi.RTM.); and CTLA-4 inhibitors such as mAb
Ipilimumab (Yervoy.RTM.); and V-domain Ig Suppressor of T Cell
Activation (VISTA) inhibitors such as mAb JNJ-61610588 (ImmuNext
Inc.).
[0015] Additional features, advantages, and embodiments of the
invention may be set forth or apparent from consideration of the
following detailed description, drawings if any, and claims.
Moreover, it is to be understood that both the foregoing summary of
the invention and the following detailed description are exemplary
and intended to provide further explanation without limiting the
scope of the invention as claimed.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows MTT assay data (72 hours) for various
concentrations of ozanimod for four human hepatocellular carcinoma
cell lines.
[0017] FIG. 2 shows MTT assay data (72 hours) for various
concentrations of ABC294640 for four human hepatocellular carcinoma
cell lines.
[0018] FIG. 3 shows MTT assay data (72 hours) for various
concentrations of SK1-I for four human hepatocellular carcinoma
cell lines.
[0019] FIG. 4A shows MTT assay data (48 hours) for various
concentrations of SK1-I for three human hepatocellular carcinoma
cell lines. FIG. 4B shows MTT assay data (48 hours) for various
concentrations of PF-543, a super potent SphK1 inhibitor, for the
same three human hepatocellular carcinoma cell lines shown in FIG.
4A.
[0020] FIGS. 5A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for Huh7 cells. SK1-I
strongly induced apoptosis in the Huh7 cells.
[0021] FIGS. 6A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for PLC-PRF5 cells.
SK1-I strongly induced apoptosis in the PLC-PRF5 cells.
[0022] FIGS. 7A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for Hep 3B cells. SK1-I
strongly induced apoptosis in the Hep 3B cells.
[0023] FIG. 8A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for Hep G2 cells. SK1-I
strongly induced apoptosis in the Hep G2 cells.
[0024] FIGS. 9A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for Huh7 cells.
Ozanimod strongly induced apoptosis in the Huh7 cells.
[0025] FIGS. 10A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for PLC-PRFS cells.
Ozanimod strongly induced apoptosis in the PLC-PRFS cells.
[0026] FIGS. 11A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for Hep 3B cells.
Ozanimod strongly induced apoptosis in the Hep 3B cells.
[0027] FIGS. 12A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for Hep G2 cells.
Ozanimod strongly induced apoptosis in the Hep G2 cells.
[0028] FIGS. 13A-D shows apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Huh7 cells.
ABC294640 failed to induce apoptosis in the Huh7 cells.
[0029] FIGS. 14A-D show apoptosis assay data for various
concentrations of ABC294640 and no-drug control for PLC-PRFS cells.
ABC294640 did not substantially induce apoptosis in the PLC-PRFS
cells.
[0030] FIGS. 15A-D show apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Hep 3B cells.
ABC294640 did not substantially induce apoptosis in the Hep 3B
cells.
[0031] FIGS. 16A-D show apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Hep G2 cells.
ABC294640 failed to induce apoptosis in the Hep G2 cells.
[0032] FIGS. 17A-C show apoptosis assay data for various
concentrations of SK1-I and no-drug control for Jurkat cells (human
T-cell leukemia cell line). SK1-I strongly induced apoptosis in the
Jurkat cells.
[0033] FIGS. 18A-C show apoptosis assay data for various
concentrations of ozanimod and no-drug control for Jurkat cells.
Ozanimod strongly induced apoptosis in the Jurkat cells.
[0034] FIGS. 19A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for primary human
hepatocytes. SK1-I did not induce apoptosis of the primary human
hepatocytes at any concentration tested.
[0035] FIGS. 20A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for primary human
hepatocytes. Ozanimod did not induce apoptosis of the primary human
hepatocytes at any concentration tested.
DETAILED DESCRIPTION
[0036] The invention provides new uses of sphingosine kinase-1
inhibitors, such as SK1-I, and selective sphingosine-1-phosphate
receptor agonists, such as ozanimod, for treating cancers, such as
a liver cancer, and myeloproliferative neoplasms
(myeloproliferative disorders), in mammals, such as human patients.
The invention also provides new uses of selective sphingosine
kinase type I inhibitors, such as SK1-I, and selective
sphingosine-1-phosphate receptor agonists, such as ozanimod, for
inducing apoptosis and/or necrosis of mammalian, such as human,
cancer cells, such as liver cancer cells, and myeloproliferative
neoplasm cells.
[0037] Sphingosine kinase 1 inhibitors used in various embodiments
of the invention may, for example, include any of those disclosed
in U.S. Pat. Nos. 8,372,888 and/or 8,314,151, each of which is
hereby incorporated by reference in its entirety herein, or
pharmaceutically acceptable salts thereof. The sphingosine kinase I
inhibitor may, for example, be (E,2R,3 S)-2-(methyl amino)-5
-(4-pentylphenyl)pent-4-ene-1,3 -diol (also known as SK1-I), or a
pharmaceutically acceptable salt thereof such as but not limited to
a hydrochloride salt. The structure of SK1-I is shown below.
##STR00001##
[0038] See also Paugh etal., Blood, 2008 112: 1382-1391.
[0039] The sphingosine kinase I inhibitor may, for example, be a
compound having the structure
##STR00002##
[0040] or a pharmaceutically acceptable salt of the compound such
as but not limited to a hydrochloride salt.
[0041] The sphingosine kinase I inhibitor may, for example, be a
compound having the structure
##STR00003##
[0042] wherein R is selected from a straight carbon chain, a
branched carbon chain, a straight carbon chain comprising one or
more heteroatoms, a branched carbon chain comprising one or more
heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring,
a hetero-aromatic ring, or any combination of the foregoing,
[0043] or a pharmaceutically acceptable salt thereof such as but
not limited to a hydrochloride salt.
[0044] The sphingosine kinase I inhibitor may, for example, be a
compound having the structure
##STR00004##
[0045] wherein R is 3,4-dimethoxy, 4-phenyl or 3-pentyl, or a
pharmaceutically acceptable salt thereof such as but not limited to
a hydrochloride salt.
[0046] Sphingosine-1-phosphate receptor agonists used in various
embodiments of the invention may, for example, be any of those
disclosed in any of U.S. Pub. Nos. 20110172202, 20130231326, and
20150299149, or pharmaceutically acceptable salts thereof. The
agonists may be agonists of one or both of sphingosine-1-phosphate
receptor-1 (S1P.sub.1) and sphingosine-1-phosphate receptor-5
(S1P.sub.b 5) and may have little or at least no substantial
agonist activity against other sphingosine-1-phosphate receptors
(in a mammal such as a human). The sphingosine-1-phosphate receptor
agonist used may, for example, be 5-[3-[(1
S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxad-
iazol-5-yl]-2-propan-2-yloxybenzonitrile (also known as ozanimod
and RPC1063) or a pharmaceutically acceptable salt thereof such as
but not limited to a hydrochloride salt. The structure of ozanimod
is shown below.
##STR00005##
[0047] See also Scott et al., British Journal of Pharmacology 2016
173:1778-1792.
[0048] The sphingosine-1-phosphate receptor agonist may, for
example, be etrasimod or a pharmaceutically acceptable salt thereof
such as but not limited to a hydrochloride salt. The structure of
etrasimod is shown below.
##STR00006##
[0049] The sphingosine-1-phosphate receptor agonist may, for
example, be amiselimod or a pharmaceutically acceptable salt
thereof such as but not limited to a hydrochloride salt. The
structure of amiselimod is shown below.
##STR00007##
[0050] ABC294640 (also known as Yeliva.RTM.) used in the
experiments presented herein is a reported sphingosine kinase-2
selective inhibitor, namely the compound (7 S)-3
-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1 -carboxamide.
The structure of ABC294640 is shown below.
##STR00008##
[0051] See also French etal., J. Pharmacol. Exp. Ther. 2010, 333,
129-139.
Experiments
[0052] MTT cell viability assays evaluating the effect of different
concentrations of each of ozanimod, ABC294640 and SK1-I on four
human hepatocellular carcinoma cell lines,
[0053] Hep G2, Hep 3B, Huh 7 and PLC-PRF5 were performed. These
four cells line were selected for the study because they are among
HCC cells lines whose gene expression profiles most closely
resemble those of primary HCC tumors. See Chen et al., BMC Medical
Genomics 2015, 8(Suppl 2):S5. The following concentrations of the
compounds were tested. [0054] Ozanimod: 200 .mu.M, 111.1 .mu.M,
61.73 .mu.M, 34.29 .mu.M, 19.05 .mu.M, 10.58 and 0 .mu.M. [0055]
ABC294640: 200 .mu.M, 111.1 .mu.M, 61.73 .mu.M, 34.29 .mu.M, 19.05
.mu.M, 10.58 and 0 .mu.M. [0056] SK1-I: 20 .mu.M, 11.11 .mu.M,
6.173 .mu.M, 3.429 .mu.M, 1.905 .mu.M, 1.058 and 0 .mu.M.
[0057] The following MTT assay protocol was followed. [0058]
Prepared stock solutions: 50 mM ozanimod, 50 mM ABC294640, 10 mM
SK1-I in DMSO. [0059] Plated 20000 cells in 160 .sub.11.1 medium
per well in 96-well plates for each cell line and incubated at
37.degree. C. overnight. [0060] Prepared compound serial dilutions:
for ozanimod and ABC294640: dilute stock 50 mM 1:50 in medium to
1000 .mu.M; for SK1-I, dilute stock 10 mM 1:50 in medium to 100
.mu.M, them make serial 1:1.8 fold serial dilution to the
titration. For negative control, diluted DMSO 1:50 to medium.
[0061] Added 40 .sub.11.1 negative control and serially titrated
compounds to 160 .mu.l of cells for each cell line. Performed in
triplicate for each cell line. [0062] Incubated at 37.degree. C.
for 72 hours. [0063] Performed assay using Vybrant MTT Cell
Proliferation Assay kit (V-13154) (Molecular Probes) from Thermo
Fisher Scientific (Waltham, Mass. USA).
[0064] The results of these 72-hour treatment MTT assays are shown
in FIGS. 1-3 as follows.
[0065] FIG. 1 shows the MTT assay data (72 hours) for ozanimod for
the four human hepatocellular carcinoma cell lines.
[0066] FIG. 2 shows the MTT assay data (72 hours) for ABC294640 for
the four human hepatocellular carcinoma cell lines.
[0067] FIG. 3 shows the MTT assay data (72 hours) for SK1-I for the
four human hepatocellular carcinoma cell lines.
[0068] 48-hour treatment MTT assays were also performed as follows.
FIG. 4A shows MTT assay data (48 hours) for various concentrations
of SK1-I for three human hepatocellular carcinoma cell lines, Hep
G2, Huh 7, and PLC-PRF5. FIG. 4B shows MTT assay data (48 hours)
for various concentrations of PF-543, a super potent SphK1
inhibitor (see Schnute et al., Biochem. J. (2012) 444, 79-88), for
the same three human hepatocellular carcinoma cell lines shown in
FIG. 4A. This data shows that SK1-I is more effective at killing
hepatocellular carcinoma cells than PF-543 despite the latter
drug's much greater potency in inhibiting SphK1.
[0069] Apoptosis/necrosis assays evaluating the effect of different
concentrations of each of ozanimod, ABC294640 and SK1-I on the four
human hepatocellular carcinoma cell lines, Hep G2, Hep 3B, Huh 7
and PLC-PRF5 were also performed.
[0070] The protocol used for the apoptosis assays was: [0071]
Plated cells in 6-well plates and incubated at 37.degree. C.
overnight. [0072] Prepared concentrations of test compound and
control compound DMSO in media. [0073] Ozanimod: 5 .mu.M, 10 and 20
.mu.M. [0074] ABC294640: 10 .mu.M, 20 and 40 .mu.M. [0075] SK1-I:
10 .mu.M, 20 and 40 .mu.M. [0076] Control: 0.2% DMSO. [0077]
Aspirated the medium from the 6-well plates and added test compound
concentrations in media or 0.2% DMSO control in media. Incubated at
37.degree. C. for 24 hours. [0078] Collected and processed the
cells following the flow cytometry protocol of the GFP
Certified.RTM. Apoptosis/Necrosis detection kit from Enzo Life
Sciences, Inc. (product no. ENZ-51002; Farmingdale, N.Y., USA).
[0079] FIGS. 5-16 present graphs plotting the data from these
24-hour apoptosis assays for the different concentrations of
compounds and no-drug control for the various cell lines. Channel
FL2 picks up the apoptosis signal and channel FL3 picks up the
necrosis signal. Data points in Quadrant 3 (Q3) in the graphs
corresponds to cells undergoing apoptosis (cells positive for the
apoptosis detection reagent of the assay). Data points in Quadrant
2 (Q2) in the graphs corresponds to cells that are positive for the
apoptosis detection reagent and positive for the necrosis detection
reagent of the assay (indicative of late-stage apoptosis).
[0080] FIGS. 5A-D show the apoptosis assay data for various
concentrations of SK1-I and no-drug control for Huh7 cells. FIG. 5A
shows the results for no-drug control. FIG. 5B shows the results
for treatment with 10 .mu.M SK1-I. FIG. 5C shows the results for
treatment with 20 .mu.M SK1-I. FIG. 5D shows the results for
treatment with 40 .mu.M SK1-I. SK1-I strongly induced apoptosis in
the Huh7 cells.
[0081] FIGS. 6A-D show the apoptosis assay data for various
concentrations of SK1-I and no-drug control for PLC-PRFS cells.
FIG. 6A shows the results for no-drug control. FIG. 6B shows the
results for treatment with 10 .mu.M SK1-I. FIG. 6C shows the
results for treatment with 20 .mu.M SK1-I. FIG. 6D shows the
results for treatment with 40 .mu.M SK1-I. SK1-I strongly induced
apoptosis in the PLC-PRFS cells.
[0082] FIGS. 7A-D show the apoptosis assay data for various
concentrations of SK1-I and no-drug control for Hep 3B cells. FIG.
7A shows the results for no-drug control. FIG. 7B shows the results
for treatment with 10 .mu.M SK1-I. FIG. 7C shows the results for
treatment with 20 .mu.M SK1-I. FIG. 7D shows the results for
treatment with 40 .mu.M SK1-I. SK1-I strongly induced apoptosis in
the Hep 3B cells.
[0083] FIGS. 8A-D show the apoptosis assay data for various
concentrations of SK1-I and no-drug control for Hep G2 cells. FIG.
8A shows the results for no-drug control. FIG. 8B shows the results
for treatment with 10 .mu.M SK1-I. FIG. 8C shows the results for
treatment with 20 .mu.M SK1-I. FIG. 8D shows the results for
treatment with 40 .mu.M SK1-I. SK1-I strongly induced apoptosis in
the Hep G2 cells.
[0084] FIGS. 9A-D show the apoptosis assay data for various
concentrations of ozanimod and no-drug control for Huh7 cells. FIG.
9A shows the results for no-drug control. FIG. 9B shows the results
for treatment with 5 .mu.M ozanimod. FIG. 9C shows the results for
treatment with 10 .mu.M ozanimod. FIG. 9D shows the results for
treatment with 20 .mu.M ozanimod. Ozanimod strongly induced
apoptosis in the Huh7 cells.
[0085] FIGS. 10A-D show the apoptosis assay data for various
concentrations of ozanimod and no-drug control for PLC-PRF5 cells.
FIG. 10A shows the results for no-drug control. FIG. 10B shows the
results for treatment with 5 .mu.M ozanimod. FIG. 10C shows the
results for treatment with 10 .mu.M ozanimod. FIG. 10D shows the
results for treatment with 20 .mu.M ozanimod. Ozanimod strongly
induced apoptosis in the PLC-PRFS cells.
[0086] FIGS. 11A-D show the apoptosis assay data for various
concentrations of ozanimod and no-drug control for Hep 3B cells.
FIG. 11A shows the results for no-drug control. FIG. 11B shows the
results for treatment with 10 .mu.M ozanimod. FIG. 11C shows the
results for treatment with 20 .mu.M ozanimod. FIG. 11D shows the
results for treatment with 40 .mu.M ozanimod. Ozanimod strongly
induced apoptosis in the Hep 3B cells.
[0087] FIGS. 12A-D show the apoptosis assay data for various
concentrations of ozanimod and no-drug control for Hep G2 cells.
FIG. 12A shows the results for no-drug control. FIG. 12B shows the
results for treatment with 10 .mu.M ozanimod. FIG. 12C shows the
results for treatment with 20 .mu.M ozanimod. FIG. 12D shows the
results for treatment with 40 .mu.M ozanimod. Ozanimod strongly
induced apoptosis in the Hep G2 cells.
[0088] FIGS. 13A-D show the apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Huh7 cells.
FIG. 13A shows the results for no-drug control. FIG. 13B shows the
results for treatment with 10 .mu.M ABC294640. FIG. 13C shows the
results for treatment with 20 .mu.M ABC294640. FIG. 13D shows the
results for treatment with 40 .mu.M ABC294640. ABC294640 failed to
induce apoptosis in the Huh7 cells.
[0089] FIGS. 14A-D show the apoptosis assay data for various
concentrations of ABC294640 and no-drug control for PLC-PRF5 cells.
FIG. 14A shows the results for no-drug control. FIG. 14B shows the
results for treatment with 10 .mu.M ABC294640. FIG. 14C shows the
results for treatment with 20 .mu.M ABC294640. FIG. 14D shows the
results for treatment with 40 .mu.M ABC294640. ABC294640 did not
substantially induce apoptosis in the PLC-PRF5 cells.
[0090] FIGS. 15A-D show the apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Hep 3B cells.
FIG. 15A shows the results for no-drug control. FIG. 15B shows the
results for treatment with 10 .mu.M ABC294640. FIG. 15C shows the
results for treatment with 20 .mu.M ABC294640. FIG. 15D shows the
results for treatment with 40 .mu.M ABC294640. ABC294640 did not
substantially induce apoptosis in the Hep 3B cells.
[0091] FIGS. 16A-D show the apoptosis assay data for various
concentrations of ABC294640 and no-drug control for Hep G2 cells.
FIG. 16A shows the results for no-drug control. FIG. 16B shows the
results for treatment with 10 .mu.M ABC294640. FIG. 16C shows the
results for treatment with 20 .mu.M ABC294640. FIG. 16D shows the
results for treatment with 40 .mu.M ABC294640. ABC294640 failed to
induce apoptosis in the Hep G2 cells.
[0092] FIGS. 17A-C show apoptosis assay data for various
concentrations of SK1-I and no-drug control for Jurkat cells (human
T-cell leukemia cell line). FIG. 17A shows the results for no-drug
control. FIG. 17B shows the results for treatment with 10 .mu.M
SK1-I. FIG. 17C shows the results for treatment with 20 .mu.M
SK1-I. SK1-I strongly induced apoptosis in the Jurkat cells.
[0093] FIGS. 18A-C show apoptosis assay data for various
concentrations of ozanimod and no-drug control for Jurkat cells.
FIG. 18A shows the results for no-drug control. FIG. 18B shows the
results for treatment with 5.mu.M ozanimod. FIG. 18C shows the
results for treatment with 10 .mu.M ozanimod. Ozanimod strongly
induced apoptosis in the Jurkat cells.
[0094] In still further experiments, the effects of SK1-I and
ozanimod on normal (non-cancerous) primary human hepatocytes were
investigated. Fresh human hepatocytes in a 12-well plate (HUF12)
were obtained from Triangle Research Labs (Durham, N.C., USA; part
of Lonza Group) and handled according to the supplier's protocol.
The shipping medium was aspirated from each well and replaced with
1 ml per well of warm Hepatocyte Maintenance Medium. The plate was
then placed in a 5% CO.sub.2 incubator at 37.degree. C. and the
hepatocytes were allowed to acclimate overnight. The Hepatocyte
Maintenance Medium was replaced before treatment with drug or
no-drug control, and the hepatocytes were treated with 0 .mu.M
(no-drug control), 10 .mu.M, 20 .mu.M, or 40 .mu.M SK1-I or 0
.mu.M, 2.5 .mu.M, 5 .mu.M, or 10 .mu.M ozanimod for 24 hours under
incubation. The cells were then harvested and analyzed using the
GFP Certified.RTM. Apoptosis/Necrosis detection kit. The results
are shown in FIGS. 19A-D for SK1-I and FIGS. 20A-D for ozanimod as
follows.
[0095] FIGS. 19A-D show apoptosis assay data for various
concentrations of SK1-I and no-drug control for primary human
hepatocytes. FIG. 19A shows the results for no-drug control. FIG.
19B shows the results for treatment with 10 .mu.M SK1-I. FIG. 19C
shows the results for treatment with 20 .mu.M SK1-I. FIG. 19D shows
the results for treatment with 40 .mu.M SK1-I. SK1-I did not induce
apoptosis of the primary human hepatocytes at any concentration
tested.
[0096] FIGS. 20A-D show apoptosis assay data for various
concentrations of ozanimod and no-drug control for primary human
hepatocytes. FIG. 20A shows the results for no-drug control. FIG.
20B shows the results for treatment with 2.5 .mu.M ozanimod. FIG.
20C shows the results for treatment with 5.mu.M ozanimod. FIG. 20D
shows the results for treatment with 10 .mu.M ozanimod. Ozanimod
did not induce apoptosis of the primary human hepatocytes at any
concentration tested.
[0097] Without limitation, the following embodiments are also
provided.
Embodiments Involving Sphingosine Kinase 1 (SphK1) Inhibitors
[0098] Embodiment 1. A method for treating liver cancer in a
mammalian subject, such as a human, including the step of:
[0099] administering to a mammalian subject in need of treatment
for liver cancer, an effective amount of a sphingosine kinase type
I inhibitor.
[0100] Embodiment 2. The method of embodiment 1, wherein the liver
cancer is hepatic cell carcinoma (HCC).
[0101] Embodiment 3. The pharmaceutical composition of embodiment
1, wherein the liver cancer is selected from the group consisting
of fibrolamellar HCC, cholangiocarcinoma (bile duct cancer) and
angiosarcoma.
[0102] Embodiment 4. The method of any one of the preceding
embodiments, wherein the sphingosine kinase type I inhibitor at
least substantially does not inhibit sphingosine kinase type
II.
[0103] Embodiment 5. The method of any one of the preceding
embodiments, wherein the sphingosine kinase type I inhibitor
includes a sphingosine kinase type I inhibitor disclosed in U.S.
Pat. Nos. 8,372,888 and/or 8,314,151, or a pharmaceutically
acceptable salt thereof.
[0104] Embodiment 6. The method of any one of embodiments 1-5,
wherein the sphingosine kinase type I inhibitor includes SK1-I or a
pharmaceutically acceptable salt thereof.
[0105] Embodiment 7. The method of any one of the preceding
embodiments, wherein said administration includes parenteral
administration.
[0106] Embodiment 8. The method of embodiment 7, wherein said
administration is via injection, such as intravenous injection,
intramuscular injection, or subcutaneous injection.
[0107] Embodiment 9. The method of any one of embodiments 1-6,
wherein said administration includes non-parenteral
administration.
[0108] Embodiment 10. The method of any one of embodiments 1-6,
wherein said administration includes oral administration by
ingestion.
[0109] Embodiment 11. The method of embodiment 10, wherein said
oral administration includes administering a dosage form including
the sphingosine kinase type I inhibitor and at least one
pharmaceutically acceptable excipient.
[0110] Embodiment 12. The method of embodiment 11, wherein the
dosage form is selected from the group consisting of a tablet, a
capsule, and a gel cap.
[0111] Embodiment 13. The method of any one of embodiments 1-6,
wherein said administration includes administration via the
alimentary canal.
[0112] Embodiment 14. The method of any one of the preceding
embodiments, further including the step of:
[0113] co-administering to the subject an effective amount of
ozanimod or a pharmaceutically acceptable salt thereof.
[0114] Embodiment 15. A pharmaceutical composition for the
treatment of a liver cancer in a mammalian subject, such as a
human, including:
[0115] a therapeutically effective amount of a sphingosine kinase
type I inhibitor.
[0116] Embodiment 16. The pharmaceutical composition of embodiment
15, wherein the liver cancer is hepatic cell carcinoma (HCC).
[0117] Embodiment 17. The pharmaceutical composition of embodiment
15, wherein the liver cancer is selected from the group consisting
of Fibrolamellar HCC, Cholangiocarcinoma (bile duct cancer) and
Angiosarcoma.
[0118] Embodiment 18. The pharmaceutical composition of any one of
the preceding embodiments, wherein the sphingosine kinase type I
inhibitor at least substantially does not inhibit sphingosine
kinase type II.
[0119] Embodiment 19. The pharmaceutical composition of any one of
the preceding embodiments, wherein the sphingosine kinase type I
inhibitor includes a sphingosine kinase type I inhibitor disclosed
in U.S. Pat. Nos. 8,372,888 and/or 8,314,151, or a pharmaceutically
acceptable salt thereof.
[0120] Embodiment 20. The pharmaceutical composition of any one of
embodiment 15-18, wherein the sphingosine kinase type I inhibitor
includes SK1-I or a pharmaceutically acceptable salt thereof.
[0121] Embodiment 21. The pharmaceutical composition of any one of
the preceding embodiments, wherein said composition is for
parenteral administration.
[0122] Embodiment 22. The pharmaceutical composition of embodiment
21, wherein said composition is for administration via injection,
such as intravenous injection, intramuscular injection, or
subcutaneous injection.
[0123] Embodiment 23. The pharmaceutical composition of any one of
embodiments 15-20, wherein said composition is for non-parenteral
administration.
[0124] Embodiment 24. The pharmaceutical composition of any one of
embodiments 15-20, wherein said composition is for oral
administration by ingestion.
[0125] Embodiment 25. The pharmaceutical composition of any one of
embodiment 15-24, further including at least one pharmaceutically
acceptable excipient.
[0126] Embodiment 26. The pharmaceutical composition of any one of
embodiments 15-25, wherein said composition is a solid dosage
form.
[0127] Embodiment 27. The pharmaceutical composition of embodiment
24, provided in a dosage form selected from the group consisting of
a liquid, a tablet, a capsule, and a gel cap.
[0128] Embodiment 28. The pharmaceutical composition of any one of
embodiments 15-20, wherein said composition is for administration
via the alimentary canal.
[0129] Embodiment 29. The pharmaceutical composition of any one of
embodiments 15-28, further including a therapeutically effective
amount of ozanimod or a pharmaceutically acceptable salt
thereof.
[0130] Embodiment 30. A method for inducing apoptosis of mammalian
liver cancer cells, such as hepatocellular carcinoma (HCC) cells,
including the step of:
[0131] contacting the mammalian liver cancer cells with an
effective amount of a selective sphingosine kinase type I
inhibitor, such as any of those disclosed in U.S. Pat. Nos.
8,372,888 and/or 8,314,151, such as SK1-I, or a pharmaceutically
acceptable salt thereof.
[0132] Embodiment 31. Use of a selective sphingosine kinase type I
inhibitor, such as any of those disclosed in U.S. Pat. Nos.
8,372,888 and/or 8,314,151, such as SK1-I, or a pharmaceutically
acceptable salt thereof, for inducing apoptosis of mammalian liver
cancer cells, such as hepatocellular carcinoma (HCC) cells.
[0133] Embodiments involving sphingosine-1-phosphate receptor
agonists
[0134] Embodiment 32. A method for treating a cancer or a
myleoproilferative disorder (myeloproliferative neoplasm) in a
mammalian subject, such as a human, including the step of:
[0135] administering to a mammalian subject in need of treatment
for a cancer or myeloproliferative disorder, a therapeutically
effective amount of a sphingosine-1-phosphate receptor agonist,
such as an agonist of one or both of sphingosine-1-phosphate
receptor-1 (S1P.sub.1) and sphingosine-1-phosphate receptor-5
(S1P.sub.5) such as ozanimod (RPC1063) or a pharmaceutically
acceptable salt thereof.
[0136] Embodiment 33. The method of embodiment 32, wherein the
myeloproliferative disorders is selected from the group consisting
of: Chronic myelogenous leukemia (e.g, BCR-ABL1-positive); Chronic
neutrophilic leukemia; Polycythemia vera; Primary myelofibrosis;
Essential thrombocythemia; Chronic eosinophilic leukemia (not
otherwise specified); and Mastocytosis.
[0137] Embodiment 34. The method of embodiment 32, wherein said
cancer is a hematological malignancy.
[0138] Embodiment 35. The method of embodiment 34, wherein said
hematological malignancy is selected from the group consisting of:
leukemias, lymphomas and myelomas.
[0139] Embodiment 36. The method of embodiment 35, wherein said
hematological malignancy is selected from the group consisting of:
Acute lymphoblastic leukemia (ALL); Acute myelogenous leukemia
(AML); Chronic lymphocytic leukemia (CLL); Chronic myelogenous
leukemia (CML); Acute monocytic leukemia (AMoL); Hodgkin's
lymphomas (e.g., any of main four subtypes); and Non-Hodgkin's
lymphomas (any subtype).
[0140] Embodiment 37. The method of embodiment of embodiment 32,
wherein said cancer is a solid organ cancer.
[0141] Embodiment 38. The method of embodiment 32, wherein the
solid organ cancer is selected from the group consisting of:
Adipose tissue cancers such as Liposarcoma,
[0142] Myxoid liposarcoma adipose; Bladder cancer; Bone cancers
such as Chondroblastoma, Chordoma, Ewings sarcoma, Osteosarcoma,
Spindle cell tumor; Brain tumors such as Ganglioneuroblastoma,
Ganglioneuroma, Glioblastoma, Malignant peripheral nerve sheath
tumor, Neuroblastoma, Neurofibroma, Schwannoma brain; Connective
tissue cancers such as Chondromyxoid fibroma, Chondrosarcoma,
Dedifferentiated chondrosarcoma, Fibromatosis, Monophasic synovial
sarcoma; Esophageal adenocarcinoma; Oral squamous cell carcinoma;
Kidney cancers such as Kidney carcinoma, Renal cell carcinoma;
Liver cancers such as Hepatocellular carcinoma (HCC), Fibrolamellar
HCC, Cholangiocarcinoma (bile duct cancer) and Angiosarcoma; Lung
cancer such as NSCLC, SCLC; Uterine tumors; Head and Neck cancers
such as head and neck squamous cell carcinoma; Ovarian tumors;
Prostate cancer; Muscle tissue cancers such as Acute quadriplegic
myopathy; Skin cancers such as Melanoma, Sarcoma, Kaposi sarcoma;
Alveolar rhabdomyo sarcoma, Embryonal rhabdomyo sarcoma,
Leiomyosarcoma; Germ cell tumors such as of the testes, testicular
cancer; and Thyroid cancer such as Thyroid adenocarcinoma.
[0143] Embodiment 39. The method of embodiment 33, wherein the
solid organ cancer is liver cancer.
[0144] Embodiment 40. The method of embodiment 39, wherein the
liver cancer is hepatic cell carcinoma (HCC).
[0145] Embodiment 41. The method of any one of embodiments 32-40,
wherein the sphingosine-1-phosphate receptor agonist at least
substantially does not agonize sphingosine-1-phosphate receptors
other than types -1 and -5.
[0146] Embodiment 42. The method of any one of embodiments 32-41,
wherein the sphingosine-1-phosphate receptor agonist includes a
sphingosine-1-phosphate receptor agonist disclosed in any of U.S.
Pub. Nos. 20110172202, 20130231326, and 20150299149 or a
pharmaceutically acceptable salt thereof.
[0147] Embodiment 43. The method of any one of embodiments 32-42,
wherein the sphingosine-1-phosphate receptor agonist includes
ozanimod or a pharmaceutically acceptable salt thereof.
[0148] Embodiment 44. The method of any one of embodiments 32-43,
wherein said administration includes parenteral administration.
[0149] Embodiment 45. The method of embodiment 44, wherein said
administration is via injection, such as intravenous injection,
intramuscular injection, or subcutaneous injection.
[0150] Embodiment 46. The method of any one of embodiments 32-43,
wherein said administration includes non-parenteral
administration.
[0151] Embodiment 47. The method of any one of embodiments 32-43,
wherein said administration includes oral administration by
ingestion.
[0152] Embodiment 48. The method of embodiment 47, wherein said
oral administration includes administering a dosage form including
the sphingosine-1-phosphate receptor agonist and at least one
pharmaceutically acceptable excipient.
[0153] Embodiment 49. The method of embodiment 48, wherein the
dosage form is selected from the group consisting of a liquid, a
tablet, a capsule, and a gel cap.
[0154] Embodiment 50. The method of any one of embodiments 32-43,
wherein said administration includes administration via the
alimentary canal.
[0155] Embodiment 51. The method of any one of embodiments 32-50,
further including the step of:
[0156] co-administering to the subject an effective amount of a
sphingosine kinase type I inhibitor, such as SK1-I, or a
pharmaceutically acceptable salt thereof.
[0157] Embodiment 52. The method of any one of embodiments 32-51,
further including the step of:
[0158] co-administering to the subject a therapeutically effective
amount of a cellular ceramide generation promoter, such as 6-[(2
S,4 R,6 E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic
acid]cyclosporin D (Valspodor; PSC833) or a pharmaceutically
acceptable salt thereof.
[0159] Embodiment 53. The method of any one of embodiments 32-52,
further including the step of:
[0160] coadministering to the subject a therapeutically effective
amount of ceramide.
[0161] Embodiment 54. A pharmaceutical composition for the
treatment of a cancer or a myeloproliferative disorder
(myeloproliferative neoplasm) in a mammalian subject, such as a
human, including:
[0162] a therapeutically effective amount of a
sphingosine-1-phosphate receptor agonist, such as an agonist of one
or both of sphingosine-1-phosphate receptor-1 (S1P.sub.1) and
sphingosine-1-phosphate receptor-5 (S1P.sub.5) such as ozanimod
(RPC1063) or a pharmaceutically acceptable salt thereof.
[0163] Embodiment 55. The pharmaceutical composition of embodiment
54, wherein the myeloproliferative disorders is selected from the
group consisting of: Chronic myelogenous leukemia
(BCR-ABL1-positive); Chronic neutrophilic leukemia; Polycythemia
vera; Primary myelofibrosis; Essential thrombocythemia; Chronic
eosinophilic leukemia (not otherwise specified); and
Mastocytosis.
[0164] Embodiment 56. The pharmaceutical composition of embodiment
54, wherein said cancer is a hematological malignancy.
[0165] Embodiment 57. The pharmaceutical composition of embodiment
56, wherein said hematological malignancy is selected from the
group consisting of: leukemias, lymphomas and myelomas.
[0166] Embodiment 58. The pharmaceutical composition of embodiment
57, wherein said hematological malignancy is selected from the
group consisting of: Acute lymphoblastic leukemia (ALL); Acute
myelogenous leukemia (AML); Chronic lymphocytic leukemia (CLL);
Chronic myelogenous leukemia (CML); Acute monocytic leukemia
(AMoL); Hodgkin's lymphomas (e.g., any of main four subtypes); and
Non-Hodgkin's lymphomas (any subtype).
[0167] Embodiment 59. The pharmaceutical composition of embodiment
of embodiment 54, wherein said cancer is a solid organ cancer.
[0168] Embodiment 60. The pharmaceutical composition of embodiment
59, wherein the solid organ cancer is selected from the group
consisting of: Adipose tissue cancers such as Liposarcoma, Myxoid
liposarcoma adipose; Bladder cancer; Bone cancers such as
Chondroblastoma, Chordoma, Ewings sarcoma, Osteosarcoma, Spindle
cell tumor; Brain tumors such as Ganglioneuroblastoma,
Ganglioneuroma, Malignant peripheral nerve sheath tumor,
Neuroblastoma, Neurofibroma, Schwannoma brain; Connective tissue
cancers such as Chondromyxoid fibroma, Chondrosarcoma,
Dedifferentiated chondrosarcoma, Fibromatosis, Monophasic synovial
sarcoma; Esophageal adenocarcinoma; Oral squamous cell carcinoma;
Kidney cancers such as Kidney carcinoma, Renal cell carcinoma;
Liver cancers such as Hepatocellular carcinoma (HCC), Fibrolamellar
HCC, Cholangiocarcinoma (bile duct cancer) and Angiosarcoma; Lung
cancer such as NSCLC, SCLC; Uterine tumors; Head and Neck cancers
such as head and neck squamous cell carcinoma; Ovarian tumors;
Prostate cancer; Muscle tissue cancers such as Acute quadriplegic
myopathy; Skin cancers such as Melanoma, Sarcoma, Kaposi sarcoma;
Alveolar rhabdomyo sarcoma, Embryonal rhabdomyo sarcoma,
Leiomyosarcoma; Germ cell tumors such as of the testes, testicular
cancer; and Thyroid cancer such as Thyroid adenocarcinoma.
[0169] Embodiment 61. The pharmaceutical composition of embodiment
59, wherein the solid organ cancer is a liver cancer.
[0170] Embodiment 62. The pharmaceutical composition of embodiment
61, wherein the liver cancer is selected from the group consisting
of hepatic cell carcinoma (HCC), fibrolamellar HCC,
cholangiocarcinoma (bile duct cancer) and angiosarcoma.
[0171] Embodiment 63. The pharmaceutical composition of any one of
embodiments 54-62, wherein the sphingosine-1-phosphate receptor
agonist at least substantially does not agonize
sphingosine-1-phosphate receptors other than types -1 and -5.
[0172] Embodiment 65. The pharmaceutical composition of any one of
embodiments 54-64, wherein the sphingosine-1-phosphate receptor
agonist includes a sphingosine-1-phosphate receptor agonist
disclosed in any of U.S. Pub Nos. 20110172202, 20130231326, and
20150299149.
[0173] Embodiment 66. The pharmaceutical composition of any one of
embodiments 54-64, wherein the sphingosine-1-phosphate receptor
agonist includes ozanimod or a pharmaceutically acceptable salt
thereof.
[0174] Embodiment 67. The pharmaceutical composition of any one of
embodiments 54-66, wherein said composition is for parenteral
administration.
[0175] Embodiment 68. The pharmaceutical composition of embodiment
67, wherein said composition is for administration via injection,
such as intravenous injection, intramuscular injection, or
subcutaneous injection.
[0176] Embodiment 69. The pharmaceutical composition of any one of
embodiments 54-66, wherein said composition is for non-parenteral
administration.
[0177] Embodiment 70. The pharmaceutical composition of any one of
embodiments 54-66, wherein said composition is for oral
administration by ingestion.
[0178] Embodiment 71. The pharmaceutical composition of any one of
embodiments 54-70, further including at least one pharmaceutically
acceptable excipient.
[0179] Embodiment 72. The pharmaceutical composition of any one of
embodiments 54-71, wherein said composition is a solid dosage
form.
[0180] Embodiment 73. The pharmaceutical composition of embodiment
72, provided in a dosage form selected from the group consisting of
a tablet, a capsule, and a gel cap.
[0181] Embodiment 74. The pharmaceutical composition of any one of
embodiments 54-66, wherein said composition is for administration
via the alimentary canal.
[0182] Embodiment 75. The pharmaceutical composition of any one of
embodiments 54-74, further including a therapeutically effective
amount of a sphingosine kinase type I inhibitor, such as one
disclosed in U.S. Pat. Nos. 8,372,888 and/or 8,314,151, such as
SK1-I, or a pharmaceutically acceptable salt thereof.
[0183] Embodiment 76. The pharmaceutical composition of any one of
embodiments 54-74, for use in combination with a therapeutically
effective amount of a sphingosine kinase type I inhibitor, such as
one disclosed in U.S. Pat. Nos. 8,372,888 and/or 8,314,151, such as
SK1-I, or a pharmaceutically acceptable salt thereof.
[0184] Embodiment 77. The pharmaceutical composition of any one of
embodiments 54-76, further including a therapeutically effective
amount of a cellular ceramide generation promoter, such as 6-[(2
S,4 R,6 E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic
acid]cyclosporin D (Valspodor; PSC833) or a pharmaceutically
acceptable salt thereof.
[0185] Embodiment 78. The pharmaceutical composition of any one of
embodiments 54-76, for use in combination with a therapeutically
effective amount of a cellular ceramide generation promoter, 6-[(2
S,4 R,6 E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic
acid]cyclosporin D (Valspodor; PSC833) or a pharmaceutically
acceptable salt thereof.
[0186] Embodiment 79. The pharmaceutical composition of any one of
embodiments 54-78 for use in combination with a therapeutically
effective amount of ceramide.
[0187] Embodiment 80. A method for inducing apoptosis of mammalian
cancer cells, such as liver cancer cells, such as hepatocellular
carcinoma (HCC) cells, including the step of:
[0188] contacting the mammalian cancer cells with an effective
amount of a sphingosine-1-phosphate receptor agonist, such as an
agonist of one or both of sphingosine-1-phosphate receptor-1
(S1P.sub.1) and sphingosine-1-phosphate receptor-5 (S1P.sub.5) such
as any of those disclosed in U.S. Pub Nos. 20110172202,
20130231326, and 20150299149, such as ozanimod (RPC1063), or a
pharmaceutically acceptable salt thereof.
[0189] Embodiment 81. Use of a sphingosine-1-phosphate receptor
agonist, such as an agonist of one or both of
sphingosine-1-phosphate receptor-1 (S1P.sub.1) and
sphingosine-1-phosphate receptor-5 (S1P.sub.5) such as any of those
disclosed in U.S. Pub Nos. 20110172202, and 20130231326, and
20150299149, such as ozanimod (RPC1063), or a pharmaceutically
acceptable salt thereof, for inducing apoptosis of mammalian cancer
cells, such as liver cancer cells, such as, hepatocellular
carcinoma (HCC) cells.
[0190] For embodiments involving ceramide, the ceramide may, for
example, be formulated/co-formulated in an acid stable lipid
vesicle/particle composition as disclosed in U.S. Pub. No.
20140271824, which is hereby incorporated by reference in its
entirety, and administered/co-administered, for example by
injection, such as intravenous injection, or orally.
[0191] Any of the method of treatment/use embodiments set forth
herein may further include the step of: co-administering one or
more immune checkpoint inhibitors, which may be monoclonal
antibodies (mABs). The immune checkpoint inhibitor may be selected
from the group consisting of the following: PD-1 inhibitors such as
mAbs Pembrolizumab (Keytruda.RTM.) and Nivolumab (Opdivo.RTM.);
PD-Ll inhibitors such as mAbs Atezolizumab (Tecentriq.RTM.),
Avelumab (Bavencio.RTM.), and Durvalumab (Imfinzi.RTM.); and CTLA-4
inhibitors such as mAb Ipilimumab (Yervoy.RTM.); and V-domain Ig
Suppressor of T Cell Activation (VISTA) inhibitors such as mAb
JNJ-61610588 (ImmuNext Inc.). Similarly, any of the pharmaceutical
composition embodiments of the invention may be for use in
combination with one or more immune checkpoint inhibitors, such as
those disclosed herein.
[0192] Still another embodiment of the invention provides a method
for treating a cancer or a myleoproliferative disorder
(myeloproliferative neoplasm), such as any of those disclosed
herein, for example, a liver cancer, in a mammalian subject, such
as a human, including the step of:
[0193] co-administering to a mammalian subject in need of treatment
for a cancer or myeloproliferative disorder, a therapeutically
effective amount of:
[0194] (a) a sphingosine kinase type I inhibitor, such as one
disclosed in U.S. Pat. Nos. 8,372,888 and/or 8,314,151, such as
SK1-I, or a pharmaceutically acceptable salt thereof; and
[0195] (b) one or more immune checkpoint inhibitors, which may be
monoclonal antibodies, such as one or more selected from the group
consisting of: PD-1 inhibitors such as mAbs Pembrolizumab
(Keytruda.RTM.) and Nivolumab (Opdivo.RTM.); PD-Ll inhibitors such
as mAbs Atezolizumab (Tecentriq.RTM.), Avelumab (Bavencio.RTM.),
and Durvalumab (Imfinzi.RTM.); and CTLA-4 inhibitors such as mAb
Ipilimumab (Yervoy.RTM.); and V-domain Ig Suppressor of T Cell
Activation (VISTA) inhibitors such as mAb JNJ-61610588 (ImmuNext
Inc.).
[0196] Immune checkpoint inhibitors may, for example, be
administered by injection in the dosages described herein and/or at
the currently approved dosages for said inhibitors.
[0197] The amount of compound that is effective for the treatment
or prevention of a condition, alone or in combination with other
compounds, may be determined by standard techniques. In addition,
in vitro and/or in vivo assays may optionally be employed to help
identify optimal dosage ranges. The precise dose to be employed
will also depend on, e.g., the route of administration and the
seriousness of the condition, and can be decided according to the
judgment of a practitioner and/or each patient's circumstances. In
other examples thereof, variations will necessarily occur depending
upon the weight and physical condition (e.g., hepatic and renal
function) of the patient being treated, the affliction to be
treated, the severity of the symptoms, the frequency of the dosage
interval, the presence of any deleterious side-effects, and the
particular compound utilized, among other things.
[0198] Administration may be as a single dose or as a divided dose.
In one embodiment, an effective dosage is administered once per
month until the condition is abated. In another embodiment, the
effective dosage is administered once per week, or twice per week
or three times per week until the condition is abated. An effective
dosage may, for example, be administered at least once daily or at
least or at least once every two-days, or at least once every three
days, four days, five days, six days or seven days. In another
embodiment, an effective dosage amount is administered about every
24 h until the condition is abated. In another embodiment, an
effective dosage amount is administered about every 12 h until the
condition is abated. In another embodiment, an effective dosage
amount is administered about every 8 h until the condition is
abated. In another embodiment, an effective dosage amount is
administered about every 6 h until the condition is abated. In
another embodiment, an effective dosage amount is administered
about every 4 h until the condition is abated.
[0199] The therapeutically effective dose may be expressed in terms
of the amount of the compound(s) or pharmaceutically acceptable
salts thereof administered per unit body weight of the subject per
day of treatment, or the total amount administered per day of
treatment. A daily dose may, for example, be at least 0.005 mg/kg
of body weight, at least 0.01 mg/kg of body weight, at least 0.025
mg/kg of body weight, at least 0.05 mg/kg of body weight, at least
0.1 mg/kg of body weight, at least 0.2 mg/kg of body weight, at
least 0.3 mg/kg of body weight, at least 0.4 mg/kg of body weight,
at least 0.5 mg/kg of body weight, at least 0.6 mg/kg of body
weight, at least 0.7 mg/kg of body weight, at least 0.8 mg/kg of
body weight, at least 0.9 mg/kg of body weight, at least 1 mg/kg of
body weight, at least 1.5 mg/kg of body weight, at least 2 mg/kg of
body weight, at least 2.5 mg/kg of body weight, at least 3 mg/kg of
body weight, at least 3.5 mg/kg of body weight, at least 4 mg/kg of
body weight, at least 4.5 mg/kg of body weight, at least 5 mg/kg of
body weight, or at one of said doses. A total daily dose may, for
example, be in the range of 0.005 mg/kg to 5 mg/kg or any subrange
or value therein, such as 0.025 to 5 mg/kg body weight, such as
0.05 to 5 mg/kg body weight. A total daily dose may, for example be
in the range of 0.1 mg to 1,000 mg total or any subrange or value
therein, such as 0.1 mg to 1,000 mg, such as 0.1 mg to 100 mg, such
as 0.1 mg to 50 mg, such as 0.5 mg to 50 mg, such as 1.0 mg to 50
mg, such as 5 mg to 50 mg, or 0.1 mg to 10 mg, such as 0.5 mg to 10
mg. For SK1-I and related SphK1 inhibitors disclosed U.S. Pat. Nos.
8,372,888 and 8,314,151, and pharmaceutically acceptable salts
thereof, a daily dose for human subjects may, for example, also be
in the range of 0.5 mg/kg to 5 mg/kg or any subrange or value
therein, such as 1 mg/kg to 4 mg/kg, such as 1 mg/kg to 3 mg/kg,
or, for example, a total daily dose of 5 mg to 50 mg or any
subrange or value therein, such as 10 mg to 40 mg, such as 20 mg to
40 mg. For ozanimod and related sphingosine-1-phosphate receptor
agonists disclosed in U.S. Pub Nos. 20110172202, 20130231326, and
20150299149, and pharmaceutically acceptable salts thereof, a daily
dose for human subjects may, for example, also be in the range of
0.1 mg to 10 mg or any subrange or value therein, such as 0.1 mg to
5 mg, such as 0.5 to 5 mg, such as 0.5 mg to 2.5 mg, such as 0.5 mg
to 1.5 mg. A pharmaceutical composition according to the invention
may, for example, include a daily dose amount of the compound as
set forth herein.
[0200] The duration of treatment by administration of a therapeutic
compound or combination according to the invention may continue for
a plurality of days, such as for at least one week, at least two
weeks, at least three weeks, at least four weeks, at least two
months, at least three months, at least four months, at least five
months, at least six months, at least seven months, at least eight
months, at least nine months, at least 10 months, at least 11
months, at least 12 months, at least 11/2 years, at least 2 years,
at least three years, at least four years, or may continue
indefinitely.
[0201] The terms co-administration and co-administering mean that
each of the things being co-administered is administered to a
subject in such temporal proximity that each (or its active
metabolite(s)) is present in active form in the subject for an at
least partially overlapping period of time. Accordingly,
co-administration may include, simultaneous administration, such as
when the things being administered are part of the same
pharmaceutical composition, or sequential administration of the
things being co-administered, for example, within the same day of
each other, within 12 hours of each other, within 6 hours of each
other, within 3 hours of each other, within 1 hours of each other,
or within 15 minutes of each other. The things being administered
may be administered by the same route, such as by oral ingestion or
injection, or by different routes.
[0202] Pharmaceutically acceptable salts and the selection and
preparation thereof are well known in the art. Such salts include
but are not limited to hydrochloride, citrate, glycolate, fumarate,
malate, tartrate, mesylate, esylate, cinnamate, isethionate,
sulfate, phosphate, diphosphate, nitrate, hydrobromide,
hydroiodide, succinate, formate, acetate, dichloroacetate, lactate,
p-toluenesulfonate, pamitate, pidolate, pamoate, salicylate,
4-aminosalicylate, benzoate, 4-acetamido benzoate, glutamate,
aspartate, glycolate, adipate, alginate, ascorbate, besylate,
camphorate, camphorsulfonate, camsylate, caprate, caproate,
cyclamate, laurylsulfate, edisylate, gentisate, galactarate,
gluceptate, gluconate, glucuronate, oxoglutarate, hippurate,
lactobionate, malonate, maleate, mandalate, napsylate,
napadisylate, oxalate, oleate, sebacate, stearate, succinate,
thiocyanate, undecylenate, and xinafoate.
[0203] It should be noted that the indefinite articles "a" and "an"
and the definite article "the" are used in the present application
to mean one or more unless the context clearly dictates otherwise.
Further, the term "or" is used in the present application to mean
the disjunctive "or" or the conjunctive "and." It should also be
understood that wherever in the present application the term
comprising or including (or a term of similar scope) is recited in
connection with the description of any embodiment or part thereof,
a corresponding embodiment or part thereof reciting instead the
term consisting essentially of or the term consisting of (or a term
of similar scope) is also disclosed.
[0204] All publications, patents, patent applications and other
documents cited in this application are hereby incorporated by
reference in their entireties for all purposes.
[0205] While various specific embodiments have been illustrated and
described, it will be appreciated that various changes can be made
without departing from the spirit and scope of the invention(s).
Moreover, features described in connection with one embodiment of
the invention may be used in conjunction with other embodiments,
even if not explicitly exemplified in combination within.
* * * * *